Cardiac and renal dysfunction is associated with progressive hearing loss in patients with Fabry disease
Maria Köping, Wafaa Shehata-Dieler, Mario Cebulla, Kristen Rak, Daniel Oder, Jonas Müntze, Peter Nordbeck, Christoph Wanner, Rudolf Hagen, Sebastian Schraven, Maria Köping, Wafaa Shehata-Dieler, Mario Cebulla, Kristen Rak, Daniel Oder, Jonas Müntze, Peter Nordbeck, Christoph Wanner, Rudolf Hagen, Sebastian Schraven
Abstract
Background: Fabry disease (FD) is an X-linked recessive hereditary lysosomal storage disorder which results in the accumulation of globotriaosylceramid (Gb3) in tissues of kidney and heart as well as central and peripheral nervous system. Besides prominent renal and cardiac organ involvement, cochlear symptoms like high-frequency hearing loss and tinnitus are frequently found with yet no comprehensive data available in the literature.
Objective: To examine hearing loss in patients with FD depending on cardiac and renal function.
Material and methods: Single-center study with 68 FD patients enrolled between 2012 and 2016 at the Department of Oto-Rhino-Laryngology, Plastic, Aesthetic and Reconstructive Head and Neck Surgery of the University of Würzburg. Every subject underwent an oto-rhino-laryngological examination as well as behavioral, electrophysiological and electroacoustical audiological testing. High-frequency thresholds were evaluated by using a modified PTA6 (0.5, 1, 2, 4, 6, 8) and HF-PTA (6, 8 kHz). Renal function was measured by eGFR, cardiac impairment was graduated by NYHA class.
Results: Sensorineural hearing loss was detected in 58.8% of the cohort, which occurred typically in sudden episodes and affected especially high frequencies. Hearing loss is asymmetric, beginning unilaterally and affecting the contralateral ear later. Tinnitus was reported by 41.2%. Renal and cardiac impairment influenced the severity of hearing loss (p < 0.05).
Conclusions: High frequency hearing loss is a common problem in patients with FD. Although not life-threatening, it can seriously reduce quality of life and should be taken into account in diagnosis and therapy. Optimized extensive hearing assessment including higher frequency thresholds should be used.
Conflict of interest statement
Competing Interests: DO received speaker's honoraria from Sanofi-Genzyme and travel assistance from Sanofi-Genzyme and Shire. JM received travel assistance from Sanofi-Genzyme, Shire and Amicus. PN received travel assistance, speaker's/advisory board honoraria, and research support from Amicus, Sanofi-Genzyme and Shire. CW received travel assistance, speaker's/advisory board honoraria, and research support from Actelion, Protalix, Sanofi-Genzyme and Shire. This does not alter our adherence to PLOS ONE policies on sharing data and materials. The other authors declare no conflicts of interest.
Figures
References
- Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M et al. (2003): Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. In: Annals of internal medicine 138 (4), S. 338–346.
- Deutsche Gesellschaft für Neurologie (DGN) (2013): Interdisziplinäre Leitlinie für die Diagnose und Therapie des Morbus Fabry.
- Biegstraaten M, Arngrímsson R; Barbey F, Boks L, Cecchi F, Deegan P et al. (2015): Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. In: Orphanet J Rare Dis 10 (1), S. 3733 doi:
- El-Abassi R, Singhal D, England JD (2014): Fabry's disease. In: Journal of the neurological sciences 344 (1–2), S. 5–19. doi:
- Meikle PJ, Hopwood JJ, Clague AE, Carey WF (1999): Prevalence of lysosomal storage disorders. In: JAMA 281 (3), S. 249–254.
- Hoffmann B, Mayatepek E (2009): Fabry disease-often seen, rarely diagnosed. In: Deutsches Ärzteblatt international 106 (26), S. 440–447. doi:
- Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H et al. (2006): High Incidence of Later-Onset Fabry Disease Revealed by Newborn Screening*. In: The American Journal of Human Genetics 79 (1), S. 31–40. doi:
- Hwu W-L, Chien Y-H, Lee N-C, Chiang S-C, Dobrovolny R, Huang A-C et al. (2009): Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A). In: Hum. Mutat. 30 (10), S. 1397–1405. doi:
- MacDermot KD, Holmes A, Miners AH (2001): Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. In: Journal of medical genetics 38 (11), S. 750–760. doi:
- Schiffmann R (2009): Fabry disease. In: Pharmacology & therapeutics 122 (1), S. 65–77. doi:
- Germain DP, Avan P, Chassaing A, Bonfils P (2002): Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients. In: BMC medical genetics 3, S. 10–20. doi:
- Conti G, Sergi B (2003): Auditory and vestibular findings in Fabry disease: a study of hemizygous males and heterozygous females. In: Acta Paediatrica 92 (0), S. 33–37. doi:
- Palla A, Hegemann S, Widmer U, Straumann D (2007): Vestibular and auditory deficits in Fabry disease and their response to enzyme replacement therapy. In: J Neurol 254 (10), S. 1433–1442. doi:
- Schachern PA, Shea DA, Paparella MM, Yoon TH (1989): Otologic histopathology of Fabry's disease. In: The Annals of otology, rhinology, and laryngology 98 (5 Pt 1), S. 359–363.
- Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO (2006): Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. In: Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association—European Renal Association 21 (2), S. 345–354. doi:
- Wraith JE, Tylki-Szymanska A, Guffon N, Lien YH, Tsimaratos M, Vellodi A et al. (2008): Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease. In: The Journal of pediatrics 152 (4), S. 563–70, 570.e1. doi:
- Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ et al. (2007): Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. In: Journal of the American Society of Nephrology: JASN 18 (5), S. 1547–1557. doi:
- Hughes DA, Elliott PM, Shah J, Zuckerman J, Coghlan G, Brookes J et al. (2008): Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. In: Heart (British Cardiac Society) 94 (2), S. 153–158. doi:
- K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification (2002). In: American journal of kidney diseases: the official journal of the National Kidney Foundation 39 (2 Suppl 1), S. S1–266.
- New York Heart Association; Dolgin M (1994): Nomenclature and criteria for diagnosis of diseases of the heart and great vessels 9th ed. Boston, Mass: Little, Brown & Co; S. 253–256.
- Kuemmerle-Deschner JB, Koitschev A, Tyrrell PN, Plontke SK, Deschner N, Hansmann S et al. (2015): Early detection of sensorineural hearing loss in Muckle-Wells-syndrome. In: Pediatr Rheumatol 13 (1), S. 1273 doi:
- Spoor A (2009): Presbycusis Values in Relation to Noise Induced Hearing Loss. In: International Audiology 6 (1), S. 48–57. doi:
- Mathers C, Smith A, Concha M. (2000): Global burden of hearing loss in the year 2000 Geneva, World Health Organization.
- Hegemann S, Hajioff D, Conti G, Beck M, Sunder-Plassmann G, Widmer U et al. (2006): Hearing loss in Fabry disease: data from the Fabry Outcome Survey. In: European journal of clinical investigation 36 (9), S. 654–662. doi:
- Limberger A, Beck M, Delgado-Sanchez S, Keilmann A (2007): Hörstörungen bei Morbus Fabry. In: HNO 55 (3), S. 185–189. doi:
- Keilmann A, Hegemann S, Conti G, Hajioff D (2006): Fabry disease and the ear In: Mehta A, Beck M, SunderPlassmann G., editors. Fabry disease. Perspectives from 5 years of FOS. Oxford: PharmaGenesis.
- Wanner C (op. 2004): Morbus Fabry. Klinik, Diagnostik und Therapie. Bremen [etc.]: UNI-MED (Uni-Med science).
- Vibert D, Blaser B, Ozdoba C, Häusler R (2006): Fabry's disease: otoneurologic findings in twelve members of one family. In: The Annals of otology, rhinology, and laryngology 115 (6), S. 412–418. doi:
- Hajioff D, Enever Y, Quiney R, Zuckerman J, Mackermot K, Mehta A (2003): Hearing loss in Fabry disease: the effect of agalsidase alfa replacement therapy. In: Journal of inherited metabolic disease 26 (8), S. 787–794. doi:
- Sergi B, Conti G, Paludetti G (2010): Inner ear involvement in Anderson-Fabry disease: long-term follow-up during enzyme replacement therapy. In: Acta otorhinolaryngologica Italica: organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale 30 (2), S. 87–93.
Source: PubMed